LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Detection of Second Primary Lymphoma in Late Diffuse Large B-cell Lymphoma Recurrences.

    Berendsen, Madeleine R / Bladel, Diede A G van / Hesius, Eva / de Groot, Fleur A / Kroeze, Leonie I / Rijntjes, Jos / Luijks, Jeroen A C W / Hoevenaars, Brigiet / Halilovic, Altuna / Nooijen, Peet / Bladel, Esther van / Jonge-Peeters, Susan de / Lensen, Chantal / Pruijt, Hans / van der Spek, Ellen / Vermaat, Joost S P / Hess, Corine / Hebeda, Konnie M / Stevens, Wendy B C /
    van Krieken, J Han J M / van den Brand, Michiel / Groenen, Patricia J T A / Scheijen, Blanca

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

    2023  Volume 36, Issue 5, Page(s) 100119

    Abstract: Approximately one-third of patients with diffuse large B-cell lymphoma (DLBCL) relapse and often require salvage chemotherapy followed by autologous stem cell transplantation. In most cases, the clonal relationship between the first diagnosis and ... ...

    Abstract Approximately one-third of patients with diffuse large B-cell lymphoma (DLBCL) relapse and often require salvage chemotherapy followed by autologous stem cell transplantation. In most cases, the clonal relationship between the first diagnosis and subsequent relapse is not assessed, thereby potentially missing the identification of second primary lymphoma. In this study, the clonal relationship of 59 paired DLBCL diagnoses and recurrences was established by next-generation sequencing-based detection of immunoglobulin gene rearrangements. Among 50 patients with interpretable results, 43 patients (86%) developed clonally related relapsed disease. This was observed in 100% of early recurrences (<2 years), 80% of the recurrences with an interval between 2 and 5 years, and 73% of late recurrences (≥5 years). On the other hand, 7 (14%) out of 50 patients displayed different dominant clonotypes in primary DLBCL and clinical recurrences, confirming the occurrence of second primary DLBCL; 37% of DLBCL recurrences that occurred ≥4 years after diagnosis were shown to be second primary lymphomas. The clonally unrelated cases were Epstein-Barr virus positive in 43% of the cases, whereas this was only 5% in the relapsed DLBCL cases. In conclusion, next-generation sequencing-based clonality testing in late recurrences should be considered in routine diagnostics to distinguish relapse from second primary lymphoma, as this latter group of patients with DLBCL may benefit from less-intensive treatment strategies.
    MeSH term(s) Humans ; Epstein-Barr Virus Infections/pathology ; Hematopoietic Stem Cell Transplantation ; Neoplasm Recurrence, Local/pathology ; Herpesvirus 4, Human ; Transplantation, Autologous ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/drug therapy
    Language English
    Publishing date 2023-02-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 645073-8
    ISSN 1530-0285 ; 0893-3952
    ISSN (online) 1530-0285
    ISSN 0893-3952
    DOI 10.1016/j.modpat.2023.100119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2450: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled Trial.

    Oerlemans, Simone / Arts, Lindy Paulina Johanna / Kieffer, Jacobien M / Prins, Judith / Hoogendoorn, Mels / van der Poel, Marjolein / Koster, Ad / Lensen, Chantal / Stevens, Wendy Bernadina Catharina / Issa, Djamila / Pruijt, Johannes F M / Oosterveld, Margriet / van der Griend, René / Nijziel, Marten / Tick, Lidwine / Posthuma, Eduardus F M / van de Poll-Franse, Lonneke V

    Journal of medical Internet research

    2021  Volume 23, Issue 12, Page(s) e27886

    Abstract: Background: There has been a cultural shift toward patient engagement in health, with a growing demand from patients to access their results.: Objective: The Lymphoma Intervention (LIVE) trial is conducted to examine the impact of return of ... ...

    Abstract Background: There has been a cultural shift toward patient engagement in health, with a growing demand from patients to access their results.
    Objective: The Lymphoma Intervention (LIVE) trial is conducted to examine the impact of return of individual patient-reported outcome (PRO) results and a web-based self-management intervention on psychological distress, self-management, satisfaction with information, and health care use in a population-based setting.
    Methods: Return of PRO results included comparison with age- and sex-matched peers and was built into the Patient-Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship registry. The self-management intervention is an adaptation of a fully automated evidence-based intervention for breast cancer survivors. Patients with lymphoma who completed the web-based questionnaire were equally randomized to care as usual, return of PRO results, and return of PRO results plus self-management intervention. Patients completed questionnaires 9 to 18 months after diagnosis (T0; n=227), 4 months (T1; n=190), 12 months (T2; n=170), and 24 months (T3; n=98).
    Results: Of all invited patients, 51.1% (456/892) responded and web-based participants (n=227) were randomly assigned to care as usual (n=76), return of PRO results (n=74), or return of PRO results and access to Living with lymphoma (n=77). Return of PRO results was viewed by 76.7% (115/150) of those with access. No statistically significant differences were observed for psychological distress, self-management, satisfaction with information provision, and health care use between patients who received PRO results and those who did not (P>.05). Use of the self-management intervention was low (2/76, 3%), and an effect could therefore not be determined.
    Conclusions: Return of individual PRO results seems to meet patients' wishes but had no beneficial effects on patient outcome. No negative effects were found when individual PRO results were disclosed, and the return of individual PRO results can therefore be safely implemented in daily clinical practice.
    Trial registration: Netherlands Trial Register NTR5953; https://www.trialregister.nl/trial/5790.
    International registered report identifier (irrid): RR2-10.1186/s13063-017-1943-2.
    MeSH term(s) Humans ; Internet ; Lymphoma/therapy ; Netherlands ; Patient Reported Outcome Measures ; Research Design
    Language English
    Publishing date 2021-12-14
    Publishing country Canada
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2028830-X
    ISSN 1438-8871 ; 1439-4456
    ISSN (online) 1438-8871
    ISSN 1439-4456
    DOI 10.2196/27886
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma.

    van Bladel, Diede A G / Stevens, Wendy B C / Kroeze, Leonie I / de Groen, Ruben A L / de Groot, Fleur A / van der Last-Kempkes, Jessica L M / Berendsen, Madeleine R / Rijntjes, Jos / Luijks, Jeroen A C W / Bonzheim, Irina / van der Spek, Ellen / Plattel, Wouter J / Pruijt, Johannes F M / de Jonge-Peeters, Susan D P W M / Velders, Gerjo A / Lensen, Chantal / van Bladel, Esther R / Federmann, Birgit / Hoevenaars, Brigiet M /
    Pastorczak, Agata / van der Werff Ten Bosch, Jutte / Vermaat, Joost S P / Nooijen, Peet T G A / Hebeda, Konnie M / Fend, Falko / Diepstra, Arjan / van Krieken, J Han J M / Groenen, Patricia J T A / van den Brand, Michiel / Scheijen, Blanca

    Blood advances

    2023  Volume 7, Issue 19, Page(s) 5911–5924

    Abstract: Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represents second primary lymphoma or an underlying T-cell lymphoma (TCL) mimicking cHL is underinvestigated. To analyze the nature of cHL recurrences, ...

    Abstract Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represents second primary lymphoma or an underlying T-cell lymphoma (TCL) mimicking cHL is underinvestigated. To analyze the nature of cHL recurrences, in-depth clonality testing of immunoglobulin (Ig) and T-cell receptor (TCR) rearrangements was performed in paired cHL diagnoses and recurrences among 60 patients, supported by targeted mutation analysis of lymphoma-associated genes. Clonal Ig rearrangements were detected by next-generation sequencing (NGS) in 69 of 120 (58%) diagnoses and recurrence samples. The clonal relationship could be established in 34 cases, identifying clonally related relapsed cHL in 24 of 34 patients (71%). Clonally unrelated cHL was observed in 10 of 34 patients (29%) as determined by IG-NGS clonality assessment and confirmed by the identification of predominantly mutually exclusive gene mutations in the paired cHL samples. In recurrences of >2 years, ∼60% of patients with cHL for whom the clonal relationship could be established showed a second primary cHL. Clonal TCR gene rearrangements were identified in 14 of 125 samples (11%), and TCL-associated gene mutations were detected in 7 of 14 samples. Retrospective pathology review with integration of the molecular findings were consistent with an underlying TCL in 5 patients aged >50 years. This study shows that cHL recurrences, especially after 2 years, sometimes represent a new primary cHL or TCL mimicking cHL, as uncovered by NGS-based Ig/TCR clonality testing and gene mutation analysis. Given the significant therapeutic consequences, molecular testing of a presumed relapse in cHL is crucial for subsequent appropriate treatment strategies adapted to the specific lymphoma presentation.
    MeSH term(s) Humans ; Hodgkin Disease/diagnosis ; Hodgkin Disease/genetics ; Hodgkin Disease/pathology ; Retrospective Studies ; Neoplasm Recurrence, Local ; Lymphoma ; Lymphoma, T-Cell ; Immunoglobulins
    Chemical Substances Immunoglobulins
    Language English
    Publishing date 2023-08-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023010412
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Administration of adjuvant oxaliplatin to patients with stage III colon cancer is affected by age and hospital.

    van Erning, Felice N / Bernards, Nienke / Creemers, Geert-Jan / Vreugdenhil, Art / Lensen, Chantal J P A / Lemmens, Valery E P P

    Acta oncologica (Stockholm, Sweden)

    2014  Volume 53, Issue 7, Page(s) 975–980

    MeSH term(s) Age Factors ; Aged ; Antineoplastic Agents/administration & dosage ; Chemotherapy, Adjuvant/statistics & numerical data ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology ; Colonic Neoplasms/surgery ; Female ; Hospitals/statistics & numerical data ; Humans ; Male ; Netherlands/epidemiology ; Odds Ratio ; Organoplatinum Compounds/administration & dosage
    Chemical Substances Antineoplastic Agents ; Organoplatinum Compounds ; oxaliplatin (04ZR38536J)
    Language English
    Publishing date 2014-07
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 896449-x
    ISSN 1651-226X ; 0349-652X ; 0284-186X ; 1100-1704
    ISSN (online) 1651-226X
    ISSN 0349-652X ; 0284-186X ; 1100-1704
    DOI 10.3109/0284186X.2013.878470
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6348: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top